Senvest Management’s Accelerate Diagnostics AXDX Stock Holding History

Senvest Management’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-26,393	Closed	-$4M	–	63
2020 Q2	$4M	Buy	+26,393	New	+$2.6M	0.25%	42

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Senvest Management's AXDX Position: Q3 2020 in Review

Senvest Management sold out of Accelerate Diagnostics (AXDX) in Q3 2020, closing a stake of 26,393 shares — an estimated $4M sold.

Senvest Management first reported a position in AXDX in Q2 2020 and held it in 1 quarter. The position peaked at $4M in Q2 2020. 112 funds tracked by Wall St. Rank hold AXDX as of Q3 2020.

Senvest Management reported no remaining Accelerate Diagnostics position as of Q3 2020 after selling out during the quarter.
Senvest Management sold 26,393 Accelerate Diagnostics shares in Q3 2020, an estimated $4M.
Senvest Management first reported a position in Accelerate Diagnostics in Q2 2020 and held it in 1 quarter.
Senvest Management's Accelerate Diagnostics position peaked at $4M in Q2 2020.
112 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2020.

Based on Senvest Management's 13F filing for Q3 2020, filed 13 Nov 2020.